Please assess the completion status of the following clinical trial:

Trial Title: Neuroprotection of Pioglitazone in Acute Ischemic Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Acute ischemic stroke onset within 48 hours~2. Age≧20 years~3. Stroke severity with at least one point for limb weakness in National Institutes of Health Stroke Scale (NIHSS).~4. The patients with no known history of diabetes with admission serum glucose ≧130 mg/dl.~Exclusion Criteria:~1. The patients who have history of urinary bladder cancer or hematuira.~2. The patients who have history of congestive heart failure or myocardial infarction.~3. The patients who have known history of using pioglitazone before the onset of stroke.~4. The patients who have mRS≧3 before stroke onset.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pioglitazone (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).